The cancer-testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo

High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells

(2011) C. Quintarelli et al.   BLOOD

Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2′-Deoxycytidine

(2011) Mengyong Yan et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

(2011) M. Lubbert et al.   HAEMATOLOGICA

The biology of cancer testis antigens: Putative function, regulation and therapeutic potential

(2011) Elisabetta Fratta et al.   Molecular Oncology

Multiple Cancer/Testis Antigens Are Preferentially Expressed in Hormone-Receptor Negative and High-Grade Breast Cancers

(2011) Yao-Tseng Chen et al.   PLoS One

De novo duplication of Xq22.1→q24 with a disruption of the NXF gene cluster in a mentally retarded woman with short stature and premature ovarian failure

(2011) Chih-Ping Chen et al.   Taiwanese Journal of Obstetrics & Gynecology

The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells

(2010) Maika Almstedt et al.   LEUKEMIA RESEARCH

Transgenic Expression of P1A Induced Thymic Tumor: A Role for Onco-Fetal Antigens in Tumorigenesis

(2010) Chi-Shan Li et al.   PLoS One

Treatment of Chronic Lymphocytic Leukemia with a Hypomethylating Agent Induces Expression of NXF2, an Immunogenic Cancer Testis Antigen

(2009) J. A. Dubovsky et al.   CLINICAL CANCER RESEARCH

Inactivation of Nxf2 causes defects in male meiosis and age-dependent depletion of spermatogonia

(2009) Jieyan Pan et al.   DEVELOPMENTAL BIOLOGY

Is there a role for the nuclear export factor 2 gene in male infertility?

(2008) Katrien Stouffs et al.   FERTILITY AND STERILITY

Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1

(2008) Naomi N. Hunder et al.   NEW ENGLAND JOURNAL OF MEDICINE